Switch theme
Sign up to access all valuation multiples
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer.
2006
7
LTM Revenue n/a
LTM EBITDA n/a
$116M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Greenwich LifeSciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Greenwich LifeSciences achieved revenue of n/a and an EBITDA of -$9.3M.
Greenwich LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Greenwich LifeSciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$8.0M | -$9.3M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$4.6M | -$7.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Greenwich LifeSciences's stock price is $9.
Greenwich LifeSciences has current market cap of $122M, and EV of $116M.
See Greenwich LifeSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $116M | $122M | XXX | XXX | XXX | XXX | $-0.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Greenwich LifeSciences has market cap of $122M and EV of $116M.
Greenwich LifeSciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Greenwich LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Greenwich LifeSciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $116M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -12.5x | XXX | XXX | XXX |
| P/E | -13.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGreenwich LifeSciences's NTM/LTM revenue growth is n/a
Greenwich LifeSciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Greenwich LifeSciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Greenwich LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Greenwich LifeSciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Greenwich LifeSciences acquired XXX companies to date.
Last acquisition by Greenwich LifeSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Greenwich LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Greenwich LifeSciences founded? | Greenwich LifeSciences was founded in 2006. |
| Where is Greenwich LifeSciences headquartered? | Greenwich LifeSciences is headquartered in United States of America. |
| How many employees does Greenwich LifeSciences have? | As of today, Greenwich LifeSciences has 7 employees. |
| Who is the CEO of Greenwich LifeSciences? | Greenwich LifeSciences's CEO is Mr. Snehal S. Patel. |
| Is Greenwich LifeSciences publicy listed? | Yes, Greenwich LifeSciences is a public company listed on NAS. |
| What is the stock symbol of Greenwich LifeSciences? | Greenwich LifeSciences trades under GLSI ticker. |
| When did Greenwich LifeSciences go public? | Greenwich LifeSciences went public in 2020. |
| Who are competitors of Greenwich LifeSciences? | Similar companies to Greenwich LifeSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Greenwich LifeSciences? | Greenwich LifeSciences's current market cap is $122M |
| Is Greenwich LifeSciences profitable? | Yes, Greenwich LifeSciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
